)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Summit Therapeutics
Summit Therapeutics (SMMT) investor relations material
Summit Therapeutics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Strategic and Clinical Highlights
Ivonescimab has completed four positive phase III studies, establishing a leadership position in the PD-1/VEGF space with a potential market exceeding $100 billion annually.
Fourteen phase III trials are ongoing or announced, with over 4,000 patients enrolled globally and more than 60,000 patients dosed commercially in China.
Ivonescimab's differentiated mechanism of action and cooperative binding properties drive its efficacy and safety profile, outperforming current PD-1 inhibitors.
The pipeline includes global phase III trials in non-small cell lung cancer and colorectal cancer, with strategic collaborations expanding into novel combinations.
Regulatory milestones include a BLA submission to the FDA in Q4 2025, with a decision expected by year-end 2026, and multiple approvals or pending indications in China.
Clinical Trial Results and Competitive Positioning
Four phase III trials have shown statistically significant, clinically meaningful improvements in progression-free and overall survival across multiple NSCLC settings.
Ivonescimab demonstrated superiority over Keytruda and other PD-1 inhibitors in head-to-head trials, with consistent efficacy across Eastern and Western populations.
Safety profile remains manageable, with low rates of discontinuation or death and consistent results across studies.
The Harmony III trial now covers two patient populations, with key data readouts expected in 2026 and 2027.
Competitors remain in earlier stages, reinforcing ivonescimab's multi-year head start in key indications.
Partnerships, Pipeline Expansion, and Financials
Collaborations with Akeso, Revolution Medicines, and GSK are expanding the reach of ivonescimab into new tumor types and combination regimens.
Over 60 investigator-sponsored trials are supported, with 15 currently enrolling, enhancing the breadth of clinical data.
Ivonescimab has been featured in 46 scientific presentations and publications, reflecting strong medical community interest.
Raised $500 million in October, bringing cash reserves to $710 million and maintaining a debt-free position to support ongoing development.
The addressable market for ivonescimab is estimated at over $100 billion, with significant potential in NSCLC and other solid tumors.
Ivonescimab MOA's competitive advantage
Capitalize on ivonescimab's first-mover status
Upcoming Phase III studies and novel combinations
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Summit Therapeutics earnings date
Q4 202525 Feb, 2026
Summit Therapeutics
Next Summit Therapeutics earnings date
Q4 202525 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Summit Therapeutics Inc., headquartered in Menlo Park, California, is a biopharmaceutical company engaged in the research and development of oncology therapies in the United States and the United Kingdom. Its lead pipeline product, ivonescimab, is a novel, bispecific antibody targeting both PD-1 and VEGF. Summit Therapeutics has also initiated two clinical trials with ivonescimab. Additionally, the company's product pipeline includes SMT-738, a novel class of precision antibiotics aimed at treating multidrug-resistant infections, including carbapenem-resistant Enterobacteriaceae infections. The company is headquartered in Menlo Park, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage